Protocol Ledger

NCT05371652 · Phase III · COMPLETED

A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants

Interventional Phase III clinical trial protocol NCT05371652 sponsored by Pfizer in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-05-19 Enrollment: 241 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05371652
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)241 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05371652
Protocol FieldVerified Registry Value
NCT IdentifierNCT05371652
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment241 participants (ACTUAL)
Registered Start Date2022-05-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI